Menganx has been approved by the US FDA, EU EMA, and Taiwan TFDA, and its efficacy and safety are supported by multiple large-scale international clinical trials. With qualified physician evaluation, proper dosage adjustment, and regular follow-up, its overall safety and efficacy are high. However, it is not suitable for everyone and is not a health supplement; it must be used under professional medical guidance.
Currently, Megagen is a self-funded treatment and is not covered by National Health Insurance. Whether it is suitable for use, the dosage, and the length of treatment need to be determined by a physician based on individual physical condition, metabolic status, and treatment goals.
No. Metronidazole is a prescription drug and must be prescribed by a physician after evaluation. Do not obtain it through online resellers, parallel imports, or unknown channels to avoid: Purchasing counterfeit drugs Incorrect dosage Serious side effects or medical risks
Due to delayed gastric emptying, the following may occur initially: Nausea, diarrhea, constipation Bloating, indigestion, decreased appetite Vomiting or abdominal pain These symptoms mostly occur during the initial dose escalation and usually subside gradually over several days to weeks. If significant redness, swelling, burning, severe pain, or persistent discomfort occurs at the injection site, please seek immediate medical attention for evaluation.
Not recommended for pregnant/breastfeeding/preparing women. (Furthermore, Meglumine may affect the absorption of oral contraceptives; it is recommended to use a non-oral contraceptive method and use contraception for at least 4 weeks.) A complete evaluation is required before use for patients with abnormal liver or kidney function, severe gastroparesis, or pancreatic or gallbladder disease. Do not use concurrently with other GLP-1 drugs. Patients with a history of depression or mood disorders should be closely monitored; if mood deteriorates, a follow-up visit should be made immediately.
The following conditions are not recommended for use or require special caution: ❌ History of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN2) ❌ Pregnant, breastfeeding, or women planning to conceive ❌ Patients with type 1 diabetes ❌ History of severe gastrointestinal disease, pancreatitis, or cholecystitis
The following groups can be assessed by a physician to determine their suitability: ✅ Obese individuals with a BMI ≥ 30 ✅ Individuals with a BMI 27–30 and comorbid metabolic diseases (such as type 2 diabetes, hypertension, fatty liver, cardiovascular risk) ✅ Individuals with type 2 diabetes ✅ Individuals with high visceral fat, difficulty controlling their diet, or those who have been stuck at a weight plateau for a long time
Metronidazole is the world’s first dual-action incretin injection that simultaneously targets both GLP-1 and GLP-1. Compared to traditional slimming pens that only target GLP-1 (such as Ozempic and Saxenda), Metronidazole can simultaneously regulate appetite, slow gastric emptying, and improve insulin sensitivity and lipid metabolism. It only requires once-weekly injections, and clinical studies have shown more comprehensive effects on weight loss and blood sugar stability. Whether side effects are fewer depends on individual constitution and dosage adjustment methods and requires evaluation by a physician.
